Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage

Fineline Cube Jul 13, 2023

The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...

Company Drug

Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA

Fineline Cube Jul 13, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Deals

DNE Group Launches $485 Million Fund for Life Sciences Park in Shanghai Pudong

Fineline Cube Jul 13, 2023

China-based infrastructure investor DNE Group has revealed that it has raised a new fund worth...

Company Deals

LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial

Fineline Cube Jul 13, 2023

Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...

Company Deals

Medidata Partners with ECCO and GoBroad to Transform Cancer Trials with Digital Tech

Fineline Cube Jul 13, 2023

Medidata, a wholly owned subsidiary of France firm Dassault Systèmes (EPA: DSY), has announced a...

Company Deals

Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential

Fineline Cube Jul 13, 2023

Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...

Company Drug

Kedrion Biopharma Achieves First Product Approval in China for Human Albumin

Fineline Cube Jul 13, 2023

Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL),...

Company Drug

GRIT Biotechnology’s GT201 TIL Therapy Approved for Clinical Studies by China’s CDE

Fineline Cube Jul 13, 2023

The Center for Drug Evaluation (CDE) website has indicated that GRIT Biotechnology, a China-based cell...

Company Deals

Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab

Fineline Cube Jul 12, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...

Company Legal / IP

Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jul 12, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a...

Company Deals Medical Device

Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations

Fineline Cube Jul 12, 2023

OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Fineline Cube Jul 12, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment

Fineline Cube Jul 12, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Deals

Next Generation Gene Therapeutics Secures $40 Million in Series B Financing for Gene Therapy Development

Fineline Cube Jul 12, 2023

Next Generation Gene Therapeutics Inc., a leading gene therapy developer based in Suzhou, China, has...

Company Deals

Ji Xing Pharmaceuticals and TSH Biopharm Announce Collaboration for Dry Eye Treatment in Taiwan

Fineline Cube Jul 12, 2023

Shanghai-based Ji Xing Pharmaceuticals, a company backed by RTW Investments, has announced a strategic collaboration...

Company Drug

Hrain Biotechnology’s Anti-CD70 T Cell Therapy HR010 Gets Tacit Approval for Renal Cancer Trial

Fineline Cube Jul 12, 2023

Shanghai-based Hrain Biotechnology Co., Ltd. has announced receiving tacit clinical trial approval from the Center...

Company Drug

Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China

Fineline Cube Jul 12, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab...

Company Deals

WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange

Fineline Cube Jul 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...

Posts pagination

1 … 547 548 549 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.